ABO Blood Groups are Not Associated with Treatment Response and Prognosis in Patients with Local Advanced Non-Small Cell Lung Cancer

Background: Lung cancer is the leading cause of cancer death, late diagnosis being the main obstacle toimproving the outcomes with stage at diagnosis as an important prognostic factor. Relationships betweenABO blood groups and risk of benign or malignant diseases have been observed and in this study, we aimedto investigate whether they might affect prognosis and response to chemoradiotherapy in patients with localadvanced non-small cell lung cancer (NSCLC). Materials and
Methods: Eighty-one patients with non-metastaticlocal advanced NSCLC were included in the study. ABO blood groups were A in 45 (55.6%), B in 7 (8.6%), ABin 8 (9.9%), and O in 21 (25.9%) patients. The patients were also divided two groups according to blood group A(45 patients) and non-A (B, AB and O; 36 patients). Response to chemoradiotherapy was complete remission in10 (12.3%), disease regression in 42 (51.9%), stable disease in 12 (14.8%), and disease progression in 17 (21.0%)patients.
Results: There was no significant difference among ABO blood group categories or between patientswith A blood group and those with non-A blood group in terms of responses to chemoradiotherapy (p>0.05).There were also no significant differences regarding overall and disease-free survival rates.
Conclusion: TheABO blood group system has no significant effect on prognosis and response to chemoradiotherapy in patientswith non-metastatic NSCLC.